Loading...

We've got a brand new version of Simply Wall St! Try it out

Becton Dickinson

SWX:BDX
Snowflake Description

Reasonable growth potential with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BDX
SWX
$67B
Market Cap
  1. Home
  2. CH
  3. Healthcare
Company description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
BDX Share Price and Events
7 Day Returns
0%
SWX:BDX
0.7%
CH Medical Equipment
-0.4%
CH Market
1 Year Returns
2.1%
SWX:BDX
33.3%
CH Medical Equipment
12.3%
CH Market
BDX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Becton Dickinson (BDX) 0% 0% 0% 2.1% 40.7% 95.7%
CH Medical Equipment 0.7% 2.5% 4.3% 33.3% 85.6% 109.4%
CH Market -0.4% 2.6% 6.7% 12.3% 21.5% 13.4%
1 Year Return vs Industry and Market
  • BDX underperformed the Medical Equipment industry which returned 33.3% over the past year.
  • BDX underperformed the Market in Switzerland which returned 12.3% over the past year.
Price Volatility
BDX
Industry
5yr Volatility vs Market

Value

 Is Becton Dickinson undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Becton Dickinson to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Becton Dickinson.

SWX:BDX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 16 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.4%
Perpetual Growth Rate 10-Year CH Government Bond Rate 3.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:BDX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate 3.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.84
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.84 (1 + (1- 21%) (29.08%))
1.022
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.02
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (1.022 * 5.96%)
9.37%

Discounted Cash Flow Calculation for SWX:BDX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Becton Dickinson is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SWX:BDX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.37%)
2020 3,442.35 Analyst x4 3,147.54
2021 3,684.22 Analyst x2 3,080.21
2022 3,884.86 Analyst x2 2,969.79
2023 4,085.38 Analyst x1 2,855.62
2024 4,268.15 Analyst x1 2,727.87
2025 4,430.10 Est @ 3.79% 2,588.90
2026 4,591.29 Est @ 3.64% 2,453.31
2027 4,753.34 Est @ 3.53% 2,322.39
2028 4,917.49 Est @ 3.45% 2,196.82
2029 5,084.67 Est @ 3.4% 2,076.97
Present value of next 10 years cash flows $26,419.00
SWX:BDX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $5,084.67 × (1 + 3.28%) ÷ (9.37% – 3.28%)
$86,209.44
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $86,209.44 ÷ (1 + 9.37%)10
$35,214.67
SWX:BDX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $26,419.00 + $35,214.67
$61,633.67
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $61,633.67 / 269.95
$228.31
SWX:BDX Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in SWX:BDX represents 0.98535x of NYSE:BDX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.98535x
Value per Share
(Listing Adjusted, CHF)
= Value per Share (USD) x Listing Adjustment Factor
= $ 228.31 x 0.98535
CHF224.97
Value per share (CHF) From above. CHF224.97
Current discount Discount to share price of CHF243.39
= -1 x (CHF243.39 - CHF224.97) / CHF224.97
-8.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Becton Dickinson is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Becton Dickinson's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Becton Dickinson's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:BDX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $3.96
NYSE:BDX Share Price ** NYSE (2019-11-14) in USD $247.01
Switzerland Medical Equipment Industry PE Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 33.29x
Switzerland Market PE Ratio Median Figure of 171 Publicly-Listed Companies 19.37x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Becton Dickinson.

SWX:BDX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:BDX Share Price ÷ EPS (both in USD)

= 247.01 ÷ 3.96

62.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Becton Dickinson is overvalued based on earnings compared to the CH Medical Equipment industry average.
  • Becton Dickinson is overvalued based on earnings compared to the Switzerland market.
Price based on expected Growth
Does Becton Dickinson's expected growth come at a high price?
Raw Data
SWX:BDX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 62.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts
39.6%per year
Switzerland Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.34x
Switzerland Market PEG Ratio Median Figure of 124 Publicly-Listed Companies 2.14x

*Line of best fit is calculated by linear regression .

SWX:BDX PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 62.43x ÷ 39.6%

1.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Becton Dickinson is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Becton Dickinson's assets?
Raw Data
SWX:BDX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $78.26
NYSE:BDX Share Price * NYSE (2019-11-14) in USD $247.01
Switzerland Medical Equipment Industry PB Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 6.21x
Switzerland Market PB Ratio Median Figure of 214 Publicly-Listed Companies 1.65x
SWX:BDX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:BDX Share Price ÷ Book Value per Share (both in USD)

= 247.01 ÷ 78.26

3.16x

* Primary Listing of Becton Dickinson.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Becton Dickinson is good value based on assets compared to the CH Medical Equipment industry average.
X
Value checks
We assess Becton Dickinson's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Becton Dickinson has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Becton Dickinson expected to perform in the next 1 to 3 years based on estimates from 16 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Becton Dickinson expected to grow at an attractive rate?
  • Becton Dickinson's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Becton Dickinson's earnings growth is expected to exceed the Switzerland market average.
  • Becton Dickinson's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:BDX Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:BDX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts 39.6%
SWX:BDX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 16 Analysts 4.6%
Switzerland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 38.7%
Switzerland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:BDX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:BDX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-09-30
2023-09-30 21,051 1
2022-09-30 19,947 4,886 4,209 5
2021-09-30 18,969 4,261 3,415 14
2020-09-30 18,023 4,221 2,432 16
2019-11-14
SWX:BDX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 17,290 3,330 1,068
2019-06-30 17,108 3,265 784
2019-03-31 17,036 2,875 926
2018-12-31 17,063 2,790 894
2018-09-30 15,983 2,865 159
2018-06-30 14,747 2,685 621
2018-03-31 13,503 2,527 -99
2017-12-31 12,251 2,555 294
2017-09-30 12,093 2,550 1,030
2017-06-30 12,158 2,129 759
2017-03-31 12,321 2,579 1,314
2016-12-31 12,419 2,411 1,309

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Becton Dickinson's earnings are expected to grow significantly at over 20% yearly.
  • Becton Dickinson's revenue is expected to grow by 4.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:BDX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below

All data from Becton Dickinson Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:BDX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30 14.65 15.15 14.15 2.00
2021-09-30 11.90 13.95 8.24 6.00
2020-09-30 11.01 12.84 8.75 5.00
2019-11-14
SWX:BDX Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 3.96
2019-06-30 2.91
2019-03-31 3.44
2018-12-31 3.33
2018-09-30 0.62
2018-06-30 2.50
2018-03-31 -0.42
2017-12-31 1.32
2017-09-30 4.70
2017-06-30 3.53
2017-03-31 6.16
2016-12-31 6.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Becton Dickinson is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Becton Dickinson's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Becton Dickinson has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Becton Dickinson performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Becton Dickinson's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Becton Dickinson's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Becton Dickinson's 1-year earnings growth exceeds its 5-year average (571.7% vs -9.4%)
  • Becton Dickinson's earnings growth has exceeded the CH Medical Equipment industry average in the past year (571.7% vs -9.5%).
Earnings and Revenue History
Becton Dickinson's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Becton Dickinson Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:BDX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 17,290.00 1,068.00 4,332.00 1,062.00
2019-06-30 17,108.00 784.00 4,331.00 1,071.00
2019-03-31 17,036.00 926.00 4,339.00 1,065.00
2018-12-31 17,063.00 894.00 4,311.00 1,073.00
2018-09-30 15,983.00 159.00 4,015.00 1,006.00
2018-06-30 14,747.00 621.00 3,689.00 947.00
2018-03-31 13,503.00 -99.00 3,325.00 857.00
2017-12-31 12,251.00 294.00 2,991.00 783.00
2017-09-30 12,093.00 1,030.00 2,925.00 774.00
2017-06-30 12,158.00 759.00 2,947.00 807.00
2017-03-31 12,321.00 1,314.00 2,957.00 827.00
2016-12-31 12,419.00 1,309.00 2,966.00 823.00
2016-09-30 12,483.00 976.00 3,005.00 828.00
2016-06-30 12,312.00 1,139.00 2,966.00 771.00
2016-03-31 12,234.00 810.00 2,988.00 743.00
2015-12-31 11,217.00 688.00 2,767.00 690.00
2015-09-30 10,282.00 695.00 2,563.00 632.00
2015-06-30 9,410.00 815.00 2,350.00 570.00
2015-03-31 8,448.00 1,079.00 2,127.00 529.00
2014-12-31 8,468.00 1,150.00 2,141.00 527.00
2014-09-30 8,446.00 1,185.00 2,145.00 524.00
2014-06-30 8,345.00 974.00 2,117.00 522.00
2014-03-31 8,239.00 941.00 2,102.00 506.00
2013-12-31 8,169.00 930.00 2,091.00 502.00
2013-09-30 8,054.00 929.00 2,059.00 494.00
2013-06-30 7,919.79 1,113.75 2,003.91 490.03
2013-03-31 7,848.32 1,132.33 1,960.04 484.02
2012-12-31 7,776.28 1,131.46 1,933.73 477.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Becton Dickinson has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Becton Dickinson used its assets less efficiently than the CH Medical Equipment industry average last year based on Return on Assets.
  • Becton Dickinson's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Becton Dickinson's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Becton Dickinson has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Becton Dickinson's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Becton Dickinson's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Becton Dickinson is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Becton Dickinson's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Becton Dickinson's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Becton Dickinson Company Filings, last reported 1 month ago.

SWX:BDX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 21,177.00 19,390.00 566.00
2019-06-30 21,497.00 20,184.00 535.00
2019-03-31 21,309.00 20,613.00 696.00
2018-12-31 21,404.00 21,071.00 948.00
2018-09-30 20,994.00 21,495.00 1,157.00
2018-06-30 21,357.00 22,250.00 1,399.00
2018-03-31 21,152.00 22,791.00 1,267.00
2017-12-31 21,247.00 22,798.00 1,208.00
2017-09-30 12,948.00 18,870.00 14,200.00
2017-06-30 12,587.00 19,016.00 13,877.00
2017-03-31 7,963.00 10,310.00 563.00
2016-12-31 7,583.00 11,017.00 967.00
2016-09-30 7,633.00 11,569.00 1,591.00
2016-06-30 8,033.00 11,931.00 1,728.00
2016-03-31 7,666.00 12,518.00 1,735.00
2015-12-31 7,223.00 12,809.00 1,606.00
2015-09-30 7,164.00 12,822.00 1,463.00
2015-06-30 7,253.00 13,171.00 1,597.00
2015-03-31 7,159.00 13,838.00 1,968.00
2014-12-31 5,068.00 10,142.00 8,794.00
2014-09-30 5,053.00 3,971.00 2,748.00
2014-06-30 5,378.00 3,973.00 2,643.00
2014-03-31 5,315.00 3,966.00 2,626.00
2013-12-31 5,078.00 3,969.00 2,513.00
2013-09-30 5,043.00 3,970.00 2,608.00
2013-06-30 4,716.52 3,970.00 2,299.20
2013-03-31 4,588.78 4,169.51 2,420.90
2012-12-31 4,469.47 4,169.84 2,513.36
  • Becton Dickinson's level of debt (91.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (79.9% vs 91.6% today).
  • Debt is not well covered by operating cash flow (17.2%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.6x coverage).
X
Financial health checks
We assess Becton Dickinson's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Becton Dickinson has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Becton Dickinson's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.25%
Current annual income from Becton Dickinson dividends. Estimated to be 1.57% next year.
If you bought CHF2,000 of Becton Dickinson shares you are expected to receive CHF25 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Becton Dickinson's pays a lower dividend yield than the bottom 25% of dividend payers in Switzerland (1.85%).
  • Becton Dickinson's dividend is below the markets top 25% of dividend payers in Switzerland (3.63%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:BDX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
Switzerland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 163 Stocks 2.9%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.8%
Switzerland Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:BDX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30 4.40 3.00
2021-09-30 3.87 5.00
2020-09-30 3.63 6.00
2019-11-14
SWX:BDX Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-07-22 3.080 1.223
2019-04-29 3.080 1.282
2019-01-22 3.080 1.256
2018-11-19 3.080 1.332
2018-07-24 3.000 1.207
2018-04-23 3.000 1.288
2018-01-22 3.000 1.340
2017-11-20 3.000 1.348
2017-07-25 2.920 1.438
2017-05-23 2.920 1.500
2017-01-23 2.920 1.605
2016-11-21 2.920 1.735
2016-07-26 2.640 1.516
2016-05-24 2.640 1.550
2016-01-26 2.640 1.734
2015-11-23 2.640 1.763
2015-07-28 2.400 1.685
2015-05-19 2.400 1.681
2015-01-27 2.400 1.677
2014-11-25 2.400 1.711
2014-07-22 2.180 1.810
2014-05-20 2.180 1.841
2014-01-28 2.180 1.913
2013-11-26 2.180 1.998
2013-07-23 1.980 1.934
2013-05-21 1.980 1.988
2013-01-29 1.980 2.140
2012-11-20 1.980 2.489
2012-07-24 1.800 2.350
2012-05-22 1.800 2.433
2012-01-31 1.800 2.340
2011-11-22 1.800 2.425
2011-07-26 1.640 2.146
2011-05-24 1.640 1.892
2011-02-01 1.640 1.996
2010-11-23 1.640 1.984
2010-07-27 1.480 2.016
2010-05-25 1.480 2.128
2010-02-02 1.480 1.922
2009-11-24 1.480 1.921
2009-07-28 1.320 1.912
2009-05-20 1.320 1.917
2009-02-03 1.320 2.001
2008-11-25 1.320 1.944

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Becton Dickinson is not paying a notable dividend for Switzerland, therefore no need to check if the payments are stable.
  • Becton Dickinson is not paying a notable dividend for Switzerland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Becton Dickinson's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Becton Dickinson's dividends as it is not paying a notable one for Switzerland.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.5x coverage).
X
Income/ dividend checks
We assess Becton Dickinson's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Becton Dickinson afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Becton Dickinson has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Becton Dickinson's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vince Forlenza
COMPENSATION $14,973,481
AGE 66
TENURE AS CEO 8.1 years
CEO Bio

Mr. Vincent A. Forlenza, also known as Vince, is a Director of Moody's Corp. since April 24, 2018. Mr. Forlenza serves as Chief Executive Officer and President of Becton, Dickinson U.K. Limited. Mr. Forlenza has been Chairman of the Board at Becton, Dickinson and Company since July 1, 2012 and has been its Chief Executive Officer since October 1, 2011. He served as President of Becton, Dickinson and Company from January 1, 2009 to April 23, 2017. He joined Becton, Dickinson and Company in 1980 and served as its Chief Operating Officer from July 29, 2010 to October 1, 2011, Executive Vice President from June 2006 to January 1, 2009, President of BD Biosciences from March 14, 2003 to June 2006 and Senior Vice President of Technology, Strategy and Development. Mr. Forlenza held leadership positions of increasing responsibility in the United States and Europe. He was instrumental in the early development of two significant new infectious disease diagnostics systems, BD ProbeTec (TM) ET and BD Phoenix (TM). Mr. Forlenza is active in various professional and community associations. He serves as Chairman of the Advanced Medical Technology Association (AdvaMed) Board of Directors. He served as the Chairman of The Valley Hospital from 2006 to 2013. Mr. Forlenza has been with BD for over 36 years in a number of different capacities, including strategic planning, business development, research and development and general management in each of BD’s segments and in overseas roles. He served as the Chairman of AdvaMed Dx at Advanced Medical Technology Association since October 2010. As AdvaMed Dx Chairman, he oversaw significant growth of the division and helped establish AdvaMed Dx as the leading advocate for the value of diagnostics. Mr. Forlenza has been a Member of The Board of Trustees of The Valley Hospital at Valley Health System, Inc. since 2002. He has been a Director at Becton, Dickinson and Company since October 1, 2011. Mr. Forlenza has the Board extensive business and industry experience, and provides the Board with a unique perspective on BD’s strategy and operations, particularly in the area of new product development. He is a member of the Board of Directors of the Quest Autism Foundation. He served on the Board of Trustees of Lehigh University. He served as a Member of the Advisory Council for the P.C. Rossin College of Engineering and Applied Sciences at Lehigh University. Mr. Forlenza obtained his BS in chemical engineering from Lehigh University in 1975 and his MBA from Wharton Graduate School, University of Pennsylvania in 1980.

CEO Compensation
  • Vince's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Vince's remuneration is higher than average for companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Becton Dickinson management team in years:

1.7
Average Tenure
54
Average Age
  • The average tenure for the Becton Dickinson management team is less than 2 years, this suggests a new team.
Management Team

Vince Forlenza

TITLE
Chairman & CEO
COMPENSATION
$15M
AGE
66
TENURE
8.1 yrs

Tom Polen

TITLE
President & COO
COMPENSATION
$6M
AGE
46
TENURE
2.6 yrs

Chris Reidy

TITLE
Executive VP
COMPENSATION
$5M
AGE
62
TENURE
6.3 yrs

Sam Khichi

TITLE
Executive VP
COMPENSATION
$4M
AGE
52
TENURE
1.9 yrs

Patrick Kaltenbach

TITLE
Executive VP & President of the Life Sciences Segment
COMPENSATION
$5M
AGE
56
TENURE
1.5 yrs

Thomas Spoerel

TITLE
VP, Controller & Chief Accounting Officer
AGE
41
TENURE
0.1 yrs

Charles Bodner

TITLE
Senior VP of Corporate Finance
AGE
48
TENURE
1.3 yrs

John DeFord

TITLE
Executive VP of Research & Development and CTO
AGE
57
TENURE
1.4 yrs

Gary DeFazio

TITLE
Senior VP

Jerry Flasz

TITLE
Executive VP of Global Services & Chief Information Officer
Board of Directors Tenure

Average tenure and age of the Becton Dickinson board of directors in years:

7.1
Average Tenure
65
Average Age
  • The tenure for the Becton Dickinson board of directors is about average.
Board of Directors

Vince Forlenza

TITLE
Chairman & CEO
COMPENSATION
$15M
AGE
66
TENURE
7.3 yrs

Bert Scott

TITLE
Independent Director
COMPENSATION
$349K
AGE
68
TENURE
17.2 yrs

Claire Fraser-Liggett

TITLE
Independent Director
COMPENSATION
$344K
AGE
64
TENURE
13 yrs

Marshall Larsen

TITLE
Lead Director
COMPENSATION
$379K
AGE
71
TENURE
4.8 yrs

Chris Jones

TITLE
Independent Director
COMPENSATION
$329K
AGE
64
TENURE
9.3 yrs

Cathy Burzik

TITLE
Independent Director
COMPENSATION
$340K
AGE
69
TENURE
6.8 yrs

Rebecca Rimel

TITLE
Independent Director
COMPENSATION
$324K
AGE
68
TENURE
7.3 yrs

Claire Pomeroy

TITLE
Independent Director
COMPENSATION
$329K
AGE
64
TENURE
5.7 yrs

Andy Eckert

TITLE
Director
COMPENSATION
$329K
AGE
57
TENURE
3.2 yrs

Dave Melcher

TITLE
Independent Director
COMPENSATION
$315K
AGE
64
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • Becton Dickinson individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
03. Sep 19 Sell Alexandre Conroy Individual 30. Aug 19 30. Aug 19 -46 CHF253.98 CHF-11,683
29. Aug 19 Sell Alexandre Conroy Individual 29. Aug 19 29. Aug 19 -9,829 CHF251.34 CHF-2,470,433
12. Aug 19 Sell Patrick Kaltenbach Individual 09. Aug 19 09. Aug 19 -127 CHF246.65 CHF-31,324
09. Aug 19 Sell Patrick Kaltenbach Individual 08. Aug 19 08. Aug 19 -150 CHF240.59 CHF-36,089
07. Aug 19 Sell Claire Fraser-Liggett Individual 07. Aug 19 07. Aug 19 -1,429 CHF236.43 CHF-337,854
13. Jun 19 Sell Simon Campion Individual 12. Jun 19 12. Jun 19 -2,903 CHF235.69 CHF-684,205
05. Jun 19 Sell Patrick Kaltenbach Individual 04. Jun 19 04. Jun 19 -275 CHF233.53 CHF-64,221
30. May 19 Sell Catherine Burzik Individual 17. Apr 19 17. Apr 19 -45 CHF225.10 CHF-10,130
30. May 19 Buy Catherine Burzik Individual 13. Apr 18 16. Apr 19 360 CHF249.66 CHF83,139
23. May 19 Sell Samrat Khichi Individual 21. May 19 21. May 19 -16,085 CHF237.13 CHF-3,814,312
14. May 19 Sell Betty Larson Individual 13. May 19 13. May 19 -450 CHF226.37 CHF-101,866
18. Mar 19 Sell Alberto Ribo Individual 15. Mar 19 15. Mar 19 -109 CHF255.77 CHF-27,879
06. Mar 19 Sell Alberto Ribo Individual 04. Mar 19 04. Mar 19 -2,021 CHF255.07 CHF-515,503
03. Dec 18 Sell James Borzi Individual 30. Nov 18 30. Nov 18 -1,825 CHF252.12 CHF-460,125
16. Nov 18 Sell Charles Bodner Individual 16. Nov 18 16. Nov 18 -950 CHF246.08 CHF-233,774
X
Management checks
We assess Becton Dickinson's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Becton Dickinson has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, thoracic and abdominal drainage, and surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Details
Name: Becton, Dickinson and Company
BDX
Exchange: SWX
Founded: 1897
$65,827,850,802
269,954,141
Website: http://www.bd.com
Address: Becton, Dickinson and Company
1 Becton Drive,
Franklin Lakes,
New Jersey, 07417,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE BDX Common Stock New York Stock Exchange US USD 02. Jan 1968
DB BOX Common Stock Deutsche Boerse AG DE EUR 02. Jan 1968
LSE 0R19 Common Stock London Stock Exchange GB USD 02. Jan 1968
SWX BDX Common Stock SIX Swiss Exchange CH CHF 02. Jan 1968
WBAG BDX Common Stock Wiener Boerse AG AT EUR 02. Jan 1968
BMV BDX * Common Stock Bolsa Mexicana de Valores MX MXN 02. Jan 1968
NYSE BDXA PFD SHS CONV A New York Stock Exchange US USD 11. May 2017
Number of employees
Current staff
Staff numbers
65,000
Becton Dickinson employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/14 21:51
End of day share price update: 2019/11/14 00:00
Last estimates confirmation: 2019/11/14
Last earnings filing: 2019/11/05
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.